1. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell D. Coll, Hasan Rajabi, Athalia Pyzer, Michal Bar-Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Kufe, and David Avigan Blood Volume 126(3):354-362 July 16, 2015 ©2015 by American Society of Hematology

2. Selective expression of MUC1 in CTCL cells. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

3. Selective expression of MUC1 in CTCL patients. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

4. GO-203 increases hydrogen peroxide (H2O2) levels in CTCL cells, which is abrogated by addition of N acetyl cysteine (NAC). Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

5. TIGAR expression is decreased by MUC1 inhibition via ROS. (A-B) HuT-78 and H9 cells were left untreated and treated with 5 μM GO-203 or 5 μM CP-2 each day for 3 days. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

6. GO-203 treatment decreases NADPH and GSH levels. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

7. MUC1-C inhibitor GO-203 is cytotoxic in CTCL cells. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology

8. MUC1-C inhibitor GO-203 is cytotoxic in CTCL primary cells at 48 and 72 hours. Salvia Jain et al. Blood 2015;126:354-362 ©2015 by American Society of Hematology